Is BPC-157 Legal in Minnesota? Federal Compounding Status

Is BPC-157 FDA-approved?

No approved product contains BPC-157 in any country FDA searched in its July 2026 review, and no US Pharmacopeia or National Formulary monograph exists for it [1]. Websites sell it as capsules, injections, oral and nasal sprays, some labeled for research use only; those are not FDA-approved drugs [1].

Where BPC-157 stands on FDA's lists

BPC-157 was in category 2 of FDA's interim compounding policies (bulk substances that may present significant safety risks) from September 2023 until April 22, 2026. It now sits in a separate 'nominated but withdrawn' table because the nominators withdrew. FDA's stated concerns about immunogenicity, peptide impurities and limited safety information remain on that page [4]. Coming off the category 2 table was not a safety finding [4].

It is in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), so the category 1 policy does not cover it [2]. It is also absent from FDA's list for outsourcing facilities [7].

What changed in 2026

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list [5]. FDA staff had recommended against listing, citing poor chemical characterization, limited safety data, weak evidence in ulcerative colitis and existing approved treatments [1]. The vote was advisory only and did not add BPC-157 to the list [5].

The October 28, 2026 HHS draft policy covers BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms. Its conditions include a patient-specific prescription, a single active ingredient, and bulk substance from an FDA-registered manufacturer with a valid certificate of analysis [8]. It is not an approval and does not put BPC-157 on any list; HHS says it 'does not establish any rights for any person and is not binding on HHS or the public' [3].

So is BPC-157 legal in Minnesota?

Minnesota's Board of Pharmacy rules in chapter 6800 include parts on compounding and dispensing (6800.3100) and compounding standards (6800.3300), which apply to pharmacies licensed in Minnesota [6]. The cited Minnesota rules are general compounding rules, so federal status is not the whole picture: compounding in Minnesota must meet both federal policy and Minnesota Board of Pharmacy requirements. Federally, BPC-157 is unapproved, and its compounding status rests on the FDA lists and the HHS draft described above. FDA found 3 adverse-event reports through December 4, 2025, all injectable BPC-157, and said it could not tell whether BPC-157 caused them; it called the clinical safety information insufficient [1].